Published • loading... • Updated
Celltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)
Summary by Financial Post
4 Articles
4 Articles
(Seoul = Yonhap News) Reporter Choi Hyeon-seok = Celltrion [068270] has received approval from Health Canada for the ophthalmic disease treatment 'EYLEA (EYLEA)...
·Korea, Republic of
Read Full ArticleCelltrion receives Health Canada approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg)
TORONTO, Ontario -- Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.1
·Canada
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left0Leaning Right2Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium

